We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
-$88.1M
Cap. Flow %
-3.63%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Healthcare 13.39%
2 Energy 1.08%
3 Technology 0.46%
4 Materials 0.45%
5 Consumer Discretionary 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPK icon
76
Opko Health
OPK
$1.23B
$5.17M 0.21%
615,157
+392,031
+176% +$5.19M
LAB icon
77
Standard BioTools
LAB
$311M
$5.09M 0.21%
628,260
+462,875
+280% +$7.29M
DVAX
78
CALL
DELISTED
Dynavax Technologies
DVAX
$5.09M 0.21%
2,073
-2,460
-54% -$69.7K
ASRT
79
CALL
DELISTED
Assertio
ASRT
$5.05M 0.21%
+45
New +$76.8K
GNCA
80
DELISTED
Genocea Biosciences, Inc.
GNCA
$5M 0.21%
91,143
+70,070
+333% +$6.95M
ALPN
81
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.99M 0.21%
96,184
-11,326
-11% -$744K
HCA icon
82
CALL
HCA Healthcare
HCA
$92.8B
$4.83M 0.2%
624
+100
+19% +$8.86K
ACHN
83
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$4.78M 0.2%
6,916
– –
ACAD icon
84
CALL
Acadia Pharmaceuticals
ACAD
$4.45B
$4.75M 0.2%
1,438
+265
+23% +$11K
ADVM
85
DELISTED
Adverum Biotechnologies
ADVM
$4.73M 0.2%
57,426
+37,646
+190% +$4.81M
CLDX icon
86
CALL
Celldex Therapeutics
CLDX
$2.79B
$4.69M 0.19%
297
+25
+9% +$7.08K
IONS icon
87
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$4.68M 0.19%
1,159
– –
DERM
88
DELISTED
Dermira, Inc.
DERM
$4.43M 0.18%
190,000
-86,994
-31% -$2.11M
GILD icon
89
Gilead Sciences
GILD
$167B
$4.43M 0.18%
+45,140
New +$5.01M
ABUS icon
90
Arbutus Biopharma
ABUS
$871M
$4.42M 0.18%
725,007
+419,656
+137% +$3.72M
RPTP
91
CALL
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$4.41M 0.18%
7,289
-1,282
-15% -$15.7K
NBIX icon
92
PUT
Neurocrine Biosciences
NBIX
$18.4B
$4.4M 0.18%
1,267
+1,026
+426% +$49.6K
INO icon
93
Inovio Pharmaceuticals
INO
$84.7M
$4.26M 0.18%
61,463
-14,037
-19% -$1.22M
ZSPH
94
PUT
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$4.2M 0.17%
640
– –
ENDP
95
CALL
DELISTED
Endo International plc
ENDP
$4.16M 0.17%
601
– –
RDUS
96
CALL
DELISTED
Radius Health, Inc.
RDUS
$4.01M 0.17%
+578
New +$40.1K
HRTX icon
97
Heron Therapeutics
HRTX
$92M
$3.91M 0.16%
+160,323
New +$5.34M
CDTX
98
DELISTED
Cidara Therapeutics
CDTX
$3.89M 0.16%
15,302
+553
+4% +$158K
OPK icon
99
CALL
Opko Health
OPK
$1.23B
$3.79M 0.16%
4,500
– –
NWBO
100
PUT
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$3.78M 0.16%
6,042
-820
-12% -$7.67K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management withdrew a net $88.1M in Q3 2015, closing 66 positions and reducing 90 holdings. Its most notable exit was iShares 20+ Year Treasury Bond ETF, an estimated $28.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 8.3% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in iShares Russell 2000 ETF worth $35.7M.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.